



## Minutes of the GM Formulary Subgroup meeting

**Date:** 6th August 2015, 12-2pm

**Venue:** Committee Room, ERC, Wythenshawe Hospital

**Present:** Monica Mason, Sarah Jacobs, Liz Bailey, Connie Chen, Charlotte Skitterall, Jonathan Peacock, Helen Burgess, Dev Devapriya

**Apologies:** Peter Howarth, Aidin Cooke, Ann Harrison, Leigh Lord, Claire Vaughan

**Declarations of interest:** none

**Item 3 – Previous minutes and actions** - The minutes from the July meeting were agreed as accurate.

**Action:** Submit to GMMMG, thereafter add to website

### **Item 4a – Final draft OAB pathway for Sept GMMMG**

SJ presented the final draft version of the OAB pathway. The FSG agreed that the pathway should be sent to the members of the OAB pathway development group for any further comment prior to submission for approval at the September GMMMG meeting.

**Action:** MM to send the final draft OAB pathway to the OAB pathway development group for final comment prior to submission to GMMMG in September.

### **Item 4b - Letter raising awareness of hyoscine butyl bromide**

Following the last FSG LL contacted Karen O'Brien (CD accountable officer) to clarify whether FSG needed to act on the NHSE letter concerning the abuse potential of hyoscine butyl bromide. Karen had responded that the letter was for primarily intended for prisons, but that there would be benefit in addressing this issue through formularies where possible. The FSG acknowledged that the GM Formulary contains hyoscine butyl bromide within chapter 4 as an alternative to mebeverine. Following consideration of prescribing data illustrating the quantities of both mebeverine and hyoscine prescribed across GM and discussion around the clinical reasons for prescribing of hyoscine the group concluded that the most appropriate way forward was for CCGs to communicate with their prescribers to raise awareness of this issue via newsletters and prescribing system alerts.

**Action:** SJ to communicate issue to GM CCGs to action with their practices.

MM to add item to formulary update paper for GMMMG

### **Item 4c – Gelclair leaflets**

GPs in Central Manchester have been receiving a letter promoting the use of Gelclair on company headed paper. It appears that it is being given out by the Christie Hospital staff. The FSG discussed the inappropriateness of this letter. It was agreed that CS would raise this at the next Chief Pharmacists meeting and MM would forward it to the GM Interface group for further action via Robert Hallworth.

**Action:** CS and MM to forward letter as agreed

### **Item 5 – Formulary amendments July 2015**

The FSG reviewed proposed formulary amendments from June and agreed the following:

- Include link to TA346 (Aflibercept for DMO) within chp 11
- Include link to TA347 (Nintedanib for previously treated locally advanced, metastatic or locally recurrent NSCLC within chp 8
- Include link to TA349 (Dexamethasone intravitreal implant for DMO) within chp 11
- Add Secukinumab and include link to TA350 (Secukinumab for treating moderate to severe plaque psoriasis) to chp 13.5.3
- Include link to MHRA warning regarding Denosumab and osteonecrosis of the jaw
- Include link to MHRA warning regarding latanoprost and eye irritation
- Include link to MHRA warning regarding SGLT2 inhibitors and risk of diabetic ketoacidosis
- Include link to MHRA warning regarding high-dose ibuprofen and CV risk
- Include link to MHRA warning regarding intrauterine contraception and the risk of uterine perforation

**Action:** MM to update formulary with amendments following approval from GMMMG

### **Item 6a – Review of formulary chapters**

Chapter 4 - SJ updated the group on the progress of the chapter 4 review. Many comments had been received following the GM-wide consultation and a meeting had been arranged with the Mental Health Trust Chief Pharmacists and a further meeting with Pain specialists to discuss tapentadol. In light of the number of comments that had been received and the many changes which were proposed for this chapter, a second GM-wide consultation was agreed by the FSG. It was agreed that the second draft chapter would come to the September FSG meeting and will then be added to the GMMMG website for consultation, with an aim to submit to GMMMG in October for approval.

There was also discussion concerning the 80/20 rule referred to within the formulary and the confusion surrounding its meaning. The FSG suggested re-phrasing this to explain that the formulary choices apply “to the majority of the population for their use in the population for that indication” or something similar. This will be discussed and a change of phrase agreed at the September FSG meeting.

It was also suggested that a link to DNP and Grey listed agents be included within the relevant formulary chapter sections. This should highlight to prescribers any agents that are less suitable for prescribing when choosing a treatment without the need to look at the separate lists. The separate lists would also remain in place. SJ will add any DNP and Grey list agents to chapter 4 as an example for discussion at the Sept FSG meeting, prior to this being considered for the other chapters.

**Action:** SJ to prepare second draft for September meeting prior to second GM-wide consultation. SJ to provide additional wording to the 80/20 rule for the September meeting

### **Item 6b – Inhaler review**

The group discussed the inhalers currently included within the formulary and those which are not. The group reviewed a draft COPD pathway which has recently be approved for use across GM by NTS and discussed the production of an asthma pathway. HB shared an asthma pathway currently in use across the Manchester CCGs. The group discussed the merits of adding in all inhaler options to both COPD and asthma pathways as a starting point for this review. Additional information would be included to aid the possibility of selection of an agents i.e. any safety concerns,

cost, patent expiry dates etc. Following consideration by the FSG these will be opened for GM-wide consultation.

**Action:** MM to prepare draft pathways with included agents for consideration at the September FSG meeting.

#### **Item 7- DNP and Grey list final draft for Sept GMMMG**

The group approved the revised DNP and Grey lists following amendments suggested at the July meeting, this will be submitted to GMMMG in September for approval.

**Action:** MM to submit revised list to September GMMMG meeting.

#### **8 – Work-plan**

The group considered the draft work plan and suggested amendments, which essentially sees the chapter reviews for the remaining chapters (4, 12, 8 and 5) being completed early in the New Year, a review of the inhaler content of the formulary and asthma and COPD pathways being completed in autumn and the development of a wound care chapter commencing in autumn.

With regards the development of a GM wound care formulary the group were made aware that Trafford CCG have a formulary which may be a useful resource, the lead reviewer will contact other GM CCGs also.

**Action:** MM to update work plan and add to web

#### **9 – Additional feedback from GMMMG/NTS/IPS**

None

#### **10 – AOB**

Request from UCHL to attend an FSG meeting - MM discussed the request from AB at UCHL to attend a FSG meeting as an observer. The group agreed that the October meeting would be best as CS is unable to attend the September meeting.

**Action:** MM to contact AB at UCHL and invite him to the October FSG meeting.

Mental Health representative to join FSG - The FSG are aware that there is currently no representative from the mental health trusts at FSG and asked that an invite be sent to the three Chief Pharmacists asking if someone is able to join the group.

**Action:** MM to email Petra Brown, Lesley Smith and Jane Wilson regarding FSG membership.

**Date of next meeting:** Thursday 3rd September 2015, 12 - 2pm  
Partington Suite, Trafford CCG